|
|
|
Volumn 16, Issue 20, 2002, Pages 35-37
|
|
The reality of targeted therapies
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
3 [(3,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE;
ABX EGF;
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CD20 ANTIGEN;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;
ERLOTINIB;
ESTROGEN RECEPTOR;
GEFITINIB;
IBRITUMOMAB TIUXETAN;
IMATINIB;
RITUXIMAB;
TAMOXIFEN;
THERATOPE;
TOSITUMOMAB I 131;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
VASCULOTROPIN INHIBITOR;
ANGIOGENESIS;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BREAST CANCER;
CANCER;
CANCER CELL;
CANCER CHEMOTHERAPY;
CANCER IMMUNOLOGY;
CANCER RESEARCH;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG MARKETING;
DRUG MECHANISM;
DRUG RESEARCH;
DRUG RESISTANCE;
DRUG SCREENING;
DRUG TARGETING;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LUNG NON SMALL CELL CANCER;
MYELOID LEUKEMIA;
NONHODGKIN LYMPHOMA;
TUMOR VASCULARIZATION;
|
|
EID: 0037078774
PISSN: 08903670
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (4)
|
|
References (1)
|
